Ascent Industries Co. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. Ascent manufactures specialty chemicals and stainless-steel pipe and tube. Results reflect continuing operations unless identified as discontinued.
Financial performance
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net sales, continuing operations | $44.1 million | $54.9 million |
| Gross profit / margin | $2.5 million / 5.7% | $1.5 million / 2.7% |
| Operating loss | $5.3 million | $6.4 million |
| Loss from continuing operations | $4.1 million | $5.8 million |
| Net loss, including discontinued operations | $5.5 million | $5.2 million |
| Basic and diluted loss per share | $0.54 | $0.51 |
| Adjusted EBITDA, continuing operations | $(3.1) million; (7.1)% of sales | $(3.7) million; (6.8)% |
Sales fell 19.6%, with average selling prices down 15.3% and pounds shipped down 7.7%. Gross profit improved on lower raw-material, shipping, and production costs, but SG&A rose to $7.8 million from $7.6 million. Interest expense declined to $0.1 million from $1.1 million, primarily due to lower debt.
Segments and discontinued operations
- Tubular Products: Sales were $23.8 million, down 23.3%. Gross profit improved to $1.1 million from a $1.4 million gross loss; operating loss narrowed to $1.5 million from $3.3 million.
- Specialty Chemicals: Sales were $20.3 million, down 14.5%. Gross profit declined to $1.6 million from $3.1 million, and the segment moved from $1.4 million operating income to a $1.4 million operating loss.
- Discontinued operations: Net loss was $1.4 million versus net income of $0.6 million. Q1 2024 included $1.1 million of Munhall asset impairments. Specialty Pipe & Tube was sold in December 2023 for approximately $55 million cash, subject to closing adjustments; its prior-period results are classified as discontinued.
Cash, debt, and liquidity
- Cash and cash equivalents were $1.3 million at March 31, versus $1.9 million at December 31, 2023. Continuing-operations operating cash flow was $0.2 million, compared with $12.4 million in Q1 2023; continuing-operations capital spending was $0.3 million.
- No borrowings were outstanding under the $80 million revolving credit facility; reported availability was $63.6 million. The company reported compliance with financial covenants. A $0.1 million insurance-premium note was outstanding at quarter-end and had a stated maturity of April 1, 2024.
- Current assets were $86.6 million and current liabilities $28.3 million. The filing reports a current ratio of 3.2. Debt-to-capital was reported as zero; operating and finance lease liabilities totaled approximately $32.1 million, with $1.5 million payable within 12 months.
- Operating cash flow benefited from a $4.0 million increase in accounts payable and a $1.2 million inventory-related cash benefit, while accounts receivable used $1.9 million. The company repurchased 16,330 shares for approximately $0.16 million.
Outlook, risks, and notable matters
- No specific revenue or earnings guidance is provided. Management expects liquidity sources to fund operations and anticipated capital expenditures, and projects up to $6.2 million of capital spending for the remainder of 2024.
- Management cites customer inventory reductions, lower demand and pricing, inflationary pressure, and higher labor and overhead costs. It warns that continued demand and cost pressures could further affect 2024 revenue, margins, and net income.
- Munhall operations were ceased in 2023; the company remains responsible for facility lease costs through 2036 and is pursuing a sublease.
- A lawsuit related to the former SPT business seeks $0.8 million plus interest and legal fees. The company recorded a $1.0 million estimated liability and says an adverse outcome could materially affect its financial statements.
- Disclosure controls were not effective at March 31, 2024 because previously reported material weaknesses in internal control over financial reporting remained unremediated. Remediation efforts are ongoing.
Important facts for investors to verify
- Whether the insurance-premium note due April 1, 2024 was repaid, and whether borrowing-base availability or covenant headroom has changed since quarter-end.
- The causes and persistence of weaker Specialty Chemicals results, sales declines, and customer inventory reductions; assess whether lower input costs can sustain improved consolidated gross margin.
- Progress on Munhall asset disposal and subleasing, including the long-term lease exposure, and developments in the SPT-related lawsuit.
- Management’s remediation milestones and evidence that material weaknesses have been resolved and controls tested effectively.
- Reconcile cash-flow disclosures: the cash-flow statement reports a $552,000 total cash decrease, while MD&A gives a $599,000 decrease for continuing operations; the filing’s presentation should be checked against the underlying statements.